Phase 2 N=10 Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease
Chronic Myeloid Leukemia · Minimal Residual Disease
Primary: Response: One Log Decrease in BCR-ABL — 3; 7 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=33 Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy
Epilepsy
Primary: Number of Subjects Reporting at Least 1 Treatment-Emergent Adverse Event (TEAE) During the Treatment Period (up to 4 Days) — 21 Subjects
Phase 2 N=44 Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders
Chronic Lymphocytic Leukemia
Primary: Overall Response — 8; 14; 19 Participants
Phase 2 N=66 Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 9.4 Weeks
Phase 2 N=72 A Study of Pemetrexed in Children With Recurrent Cancer
Osteosarcoma · Medulloblastoma · Sarcoma, Ewing's
Primary: Percentage of Participants With Overall Tumor Response (Response Rate) — 0; 0; 0; 0 Percentage of Participants
Phase 2 N=5 Dexamethasone Treatment of Congenital Adrenal Hyperplasia
Adrenal Hyperplasia, Congenital
Primary: Percent Difference in the Mean Log Transformed Area Under the Curve of 17-hydroxyprogesterone Between Regimens — 3.16; 3.91 Log Mean Area Under the Curve — p=0.09
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Phase 2 N=189 Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
Neoplasms, Breast
Primary: Percentage of Participants With Progressive Disease at Week 12 in Cohort 1 — 38.9; 36.2; 43.1; 37.7 percentage of participants — p=0.3724
Phase 2 N=59 Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder
Depression · Major Depressive Disorder
Primary: Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) — 0; 0; 0; 0 participants
Phase 2 N=48 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
Cutaneous B-cell Non-Hodgkin Lymphoma · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue · Intraocular Lymphoma
Primary: Number of Patients With Objective Response — 10; 8 participants
Phase 2 N=41 A Phase II Study of CC-5013 in Myelofibrosis
Myelofibrosis
Primary: Efficacy of CC-5013 in Myelofibrosis — 7; 9; 12; 9 Participants
Phase 2 N=24 Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects
HIV Infections
Primary: HIV Viral Load — -0.18; -0.05; 0.002; 0.26 HIV RNA copies/mL — p=0.008
Phase 2 N=30 Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma
Primary: Overall Response Rate (ORR) at the Completion of Induction Chemotherapy, Which is the Percent of Complete Responses (CR) Plus Percent of Partial Responses (PR). — 90…
Phase 2 N=34 Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
Acute Myelogenous Leukemia · Myelodysplastic Syndrome · Leukemia
Primary: Number of Participants With Complete Remission — 0; 0; 0; 2 participants
Phase 2 N=112 Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
West Nile Fever
Primary: Number of Participants With Fourfold or Greater Post-vaccination Titers (Seroconversion). — 0; 21; 36; 27 Participants